Matinas BioPharma Holdings (MTNB) Total Liabilities (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Total Liabilities of $2.9 million for Q1 2026, down 50.53% year-over-year from $5.8 million in Q1 2025, and up 19.93% quarter-over-quarter from $2.4 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Total Liabilities (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Total Liabilities for 14 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 50.53% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 50.53% YoY), while the FY2025 annual figure was $2.4 million, down 52.92% from the prior year.
- Total Liabilities advanced to $2.9 million in Q1 2026 per MTNB's latest filing, from $2.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $9.6 million in Q2 2022 and bottomed at $2.4 million in Q4 2025.
- Historically, Total Liabilities has averaged $5.7 million across 5 years, with a median of $5.6 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 39.84% — and 2025, when it tumbled 52.92%.
- Matinas BioPharma Holdings' Total Liabilities stood at $8.2 million in 2022, then fell by 28.4% to $5.9 million in 2023, then declined by 13.78% to $5.1 million in 2024, then sank by 52.92% to $2.4 million in 2025, then grew by 19.93% to $2.9 million in 2026.
- Business Quant data shows MTNB's Total Liabilities at $2.9 million in Q1 2026, $2.4 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 2.85 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 5.77 Mn |
| Dec 31, 2024 | 5.05 Mn |
| Sep 30, 2024 | 4.80 Mn |
| Jun 30, 2024 | 5.26 Mn |
| Mar 31, 2024 | 5.05 Mn |
| Dec 31, 2023 | 5.86 Mn |
| Sep 30, 2023 | 6.64 Mn |
| Jun 30, 2023 | 6.17 Mn |
| Mar 31, 2023 | 5.64 Mn |
| Dec 31, 2022 | 8.18 Mn |
| Sep 30, 2022 | 8.93 Mn |
| Jun 30, 2022 | 9.57 Mn |
| Mar 31, 2022 | 8.10 Mn |
| Dec 31, 2021 | 8.83 Mn |
| Sep 30, 2021 | 8.73 Mn |